Social News
Written by: Zheng Cuibi
2021-04-12 14:28
Last update date: 2021-04-12 14:28
Kexing Biotechnology Co., Ltd. has conducted phase 3 clinical studies on the new crown vaccine in many countries, including Brazil. However, after the Brazilian research institute briefly announced the effective data in mid-January, it has not released a complete report.
He Boliang, director of the Infection and Infectious Diseases Center of the University of Hong Kong, said today (12th) that Brazilian research institutions have finally completed the research article, but the report has not been approved by the peers and has not yet been published in scientific journals.
The content of the report pointed out that the effective rate of Kexing vaccine was 50.7%. During the study period, one vaccinated participant died. The incident involved an overdose, but it was said that it had nothing to do with the vaccine.
▼On March 22, Chief Executive Carrie Lam led the Secretary to receive the second dose of Kexing vaccine▼
+4
+4
+4
According to the report, between July and December last year, 12,396 medical staff between 18 and 59 years old participated in the third phase of Kexing Vaccine. They received at least one dose of vaccine or placebo, and 9823 of them received two doses. needle.
There were 6195 people in the vaccinated group and 6,201 people in the control group.
Among the 4,953 people in the vaccination group, 85 were diagnosed; among the 4,870 people in the control group, 168 were diagnosed.
Researchers said that the effective rate of Kexing vaccine for all cases is 50.7%, the effective rate of mild cases is 83.7%, and the effective rate of severe cases is 100%.
Kexing vaccine.
(Profile picture)
The report also pointed out that if the interval between the two doses of vaccine is more than 21 days, the effective rate is 62.3%. Although the number of people studying the interval between the two doses is not large, it is still seen that more than 21 days is more effective. The researchers recommend two doses. The needles were inoculated 28 days apart.
In addition, the report stated that the elders over the age of 60 in the test had a lower immune response to the vaccine, contrary to the results of earlier studies.
However, there is no data to confirm the effectiveness of only one dose of the vaccine, but after the first injection, the effective effect began to be seen in the second week after the first injection.
In terms of side effects, six adults suffer from needle and mouth pain, 34% have headaches, and 0.2% have fever.
In addition, during the study period, 64 participants reported 67 serious abnormal events, including two deaths, but both were classified as not related to the vaccine. One was in the control group and died of cardiopulmonary arrest; the other was in the vaccinated group , The report only mentions overdose.
He Boliang.
(Profile picture)
He Boliang believes that the report contains insufficient information on the type of virus, and it is difficult to know the effective rate and antibody level of the Coxing vaccine against the Brazilian variant virus.
Kexing Vaccine | Drainage Services Department staff suddenly fainted while being sent to hospital and died 23 days before the injection
New crown vaccine | Department of Health receives 6 more reports of facial paralysis, 5 people beat Kexing, 1 person beat Bitai
Europe says AstraZeneca may cause thrombosis
17,000 people did not get the second dose of Kexing vaccine on time. The research reveals that the protection rate of only the first shot is only 3%?
01News
New crown pneumonia new crown vaccine vaccine vaccination China Kexing
